appoints Kathryn Corzo as Chief Operating Officer

Cell coding company today announces the key appointment of Kathryn Corzo as Chief Operating Officer. She started in the role on 1 November 2021. appoints kathryn corzo as chief operating officer
From left: CEO Mark Kotter, CBO Paul Morrill, COO Kathryn Corzo, Co-Founder Florian Schuster, CMO Ramy Ibrahim. Image Credit:

Corzo is a highly regarded biotechnology executive with extensive experience in early and late drug development across multiple indications and platforms. Most recently she was partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, where she built capabilities and oversaw a cutting edge oncology cell therapy portfolio including CAR-T, CAR-NK, iPSC and gamma-delta platforms. She also served on Takeda’s R&D Management Committee, was a member of Takeda’s Oncology Leadership Team and served on the board of directors for Maverick Therapeutics which was acquired by Takeda in March 2021.

Previously, Corzo was Sanofi Genzyme’s Vice President R&D Myeloma Head where she led global registration programs to drug approvals in the US, EU and Japan. In addition, she held various R&D leadership roles at Hoffmann-La-Roche, Roche Molecular Systems, Eli Lilly and Syndax, contributing to the initial approval of 6 innovative cancer medicines and multiple indication expansions across the globe.

As COO, Corzo will sit on’s executive team and oversee all global operations. The appointment is key for as they develop their human cells for therapeutic applications. She will also oversee all operations for the continued expansion of the ioCells portfolio which provides human cells and disease models for research and drug discovery.

My passion and life work is to deliver transformative therapies for patients in need. Cell therapies hold significant promise yet R&D is extremely expensive and complex. has a unique platform technology to address many challenges of cell therapy development by providing consistency, speed and scale with its novel approach to cell coding and reprogramming. As an emerging biotech company has profound growth possibilities. It’s perfect timing for me to join and leverage my experience to build the company for success. ”

Kathryn Corzo, Chief Operating Officer

Kathryn brings a wealth of relevant experience and expertise as well as leadership. I welcome her into our company and look forward to working with her to deliver on the promise of our technology for patients. ”

Mark Kotter Founder, CEO



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA (2021, November 19). appoints Kathryn Corzo as Chief Operating Officer. AZoLifeSciences. Retrieved on June 24, 2024 from

  • MLA " appoints Kathryn Corzo as Chief Operating Officer". AZoLifeSciences. 24 June 2024. <>.

  • Chicago " appoints Kathryn Corzo as Chief Operating Officer". AZoLifeSciences. (accessed June 24, 2024).

  • Harvard 2021. appoints Kathryn Corzo as Chief Operating Officer. AZoLifeSciences, viewed 24 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like... launches Huntington’s disease human cell model